Bone
Volume 42, Issue 4 , Pages 616-622 , April 2008

Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1)

  • Aaron Schindeler

      Affiliations

    • Corresponding Author InformationCorresponding author. Orthopaedic Research & Biotechnology Research Building, The Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW 2145, Australia. Fax: +43 61 2 98453078.
    • ,
  • David G. Little

Received 12 September 2007 ,Revised 5 November 2007 ,Accepted 13 November 2007.

References 

  1. Neurofibromatosis . Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575–578
  2. Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988;111:1355–1381
  3. Viskochil D. Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol. 2002;17:562–570
  4. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990;249:181–186
  5. Young H, Hyman S, North K. Neurofibromatosis 1: clinical review and exceptions to the rules. J Child Neurol. 2002;17:613–621
  6. Viskochil D. In search of the Holy Grail: NF1 mutation analysis and genotype–phenotype correlation. Genet Med. 1999;1:245–247
  7. Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci USA. 1991;88:9658–9662
  8. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in hematopoietic cells. Nat Genet. 1996;12:144–148
  9. McCormick F. Ras signaling and NF1. Curr Opin Genet Dev. 1995;5:51–55
  10. Klose A, Ahmadian MR, Schuelke M, et al. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum Mol Genet. 1998;7:1261–1268
  11. Kuorilehto T, Poyhonen M, Bloigu R, Heikkinen J, Vaananen K, Peltonen J. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int. 2005;16:928–936
  12. Lammert M, Kappler M, Mautner VF, Lammert K, Storkel S, Friedman JM, et al. Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int. 2005;16:1161–1166
  13. Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, Carey JC, et al. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr. 2007;150:83–88
  14. Dulai S, Briody J, Schindeler A, North KN, Cowell CT, Little DG. Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop. 2007;27:472–475
  15. Malminen M, Peltonen S, Koivunen J, Peltonen J. Functional expression of NF1 tumor suppressor protein: association with keratin intermediate filaments during the early development of human epidermis. BMC Dermatol. 2002;2:10
  16. Hirvonen O, Lakkakorpi J, Aaltonen V, Hirvonen H, Rossi M, Karvonen SL, et al. Developmental regulation of NF1 tumor suppressor gene in human peripheral nerve. J Neurocytol. 1998;27:939–952
  17. Huynh DP, Nechiporuk T, Pulst SM. Differential expression and tissue distribution of type I and type II neurofibromins during mouse fetal development. Dev Biol. 1994;161:538–551
  18. Gutmann DH, Geist RT, Wright DE, Snider WD. Expression of the neurofibromatosis 1 (NF1) isoforms in developing and adult rat tissues. Cell Growth Differ. 1995;6:315–323
  19. Kuorilehto T, Nissinen M, Koivunen J, Benson MD, Peltonen J. NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos. J Bone Miner Res. 2004;19:983–989
  20. Wu X, Estwick SA, Chen S, Yu M, Ming W, Nebesio TD, et al. Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Hum Mol Genet. 2006;15:2837–2845
  21. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994;8:1019–1029
  22. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994;7:353–361
  23. Cichowski K, Shih TS, Schmitt E, Santiago S, Reilly K, McLaughlin ME, et al. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286:2172–2176
  24. Vogel KS, Klesse LJ, Velasco-Miguel S, Meyers K, Rushing EJ, Parada LF. Mouse tumor model for neurofibromatosis type 1. Science. 1999;286:2176–2179
  25. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296:920–922
  26. Kolanczyk M, Kossler N, Kühnisch J, Lavitas L, Stricker S, Wilkening U, et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet. 2007;16:874–886
  27. Menon AG, Anderson KM, Riccardi VM, Chung RY, Whaley JM, Yandell DW, et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc Natl Acad Sci USA. 1990;87:5435–5439
  28. Spurlock G, Griffiths S, Uff J, Upadhyaya M. Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. Fam Cancer. 2007;[Jun 6 Electronic publication ahead of print]
  29. Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet. 2006;79:143–148
  30. Alwan S, Tredwell SJ, Friedman JM. Is osseous dysplasia a primary feature of neurofibromatosis 1 (NF1)?. Clin Genet. 2005;67:378–390
  31. Little DG, Ramachandran M, Schindeler A. The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br. 2007;89-B:425–433
  32. Yu X, Chen S, Potter OL, Murthy SM, Li J, Pulcini JM, et al. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone. 2005;36:793–802
  33. Schindeler A, Ramachandran M, Godfrey C, Morse A, McDonald M, Mikulec K, et al. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild type and Nf1 haploinsufficient mice. J Orthop Res. 2008;26(1):65–74
  34. Klein BY, Rojansky N, Gal I, Shlomai Z, Liebergall M, Ben-Bassat H. Analysis of cell-mediated mineralization in culture of bone-derived embryonic cells with neurofibromatosis. J Cell Biochem. 1995;57:530–542
  35. Nakayama K, Tamura Y, Suzawa M. Receptor tyrosine kinases inhibit Bone Morphogenetic Protein-Smad responsive promoter activity and differentiation of murine MC3T3-E1 osteoblast-like cells. J Bone Miner Res. 2003;5:827–835
  36. Kretzschmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature. 1997;389:618–622
  37. Schindeler A, Little DG. Ras-MAPK signaling in osteogenic differentiation: friend or foe?. J Bone Miner Res. 2006;21:1331–1338
  38. Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, et al. Hyperactivation of p21 and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest. 2006;116:2880–2891
  39. Miyazaki T, Katagiri H, Kanegae Y, Takayanagi H, Sawada Y, Yamamoto A, et al. Reciprocal role of ERK and NF-κB pathways in survival and activation of osteoclasts. J Cell Biol. 2000;148:333–342
  40. Nakamura H, Hirata A, Tsuji T, Yamamoto T. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res. 2003;18:1198–1205
  41. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17–25
  42. Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, Ron D, et al. ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab. 2006;4:441–451
  43. Cho TJ, Seo JB, Kim JA, Lee DY, Yoo WJ, Chung CY, et al. Fibrous hamartoma at atrophic congenital pseudoarthrosis of the tibia is not osteogenic but osteoclastogenic. Transactions Orthop Res Soc (San Diego, CA). 2007;32:0922;[abstract]
  44. Illes T, Halmai V, de Jonge T, Dubousset J. Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int. 2001;12:823–827
  45. Yu X, Milas J, Watanabe N, Rao N, Murthy S, Potter OL, et al. Neurofibromatosis type 1 gene haploinsufficiency reduces AP-1 gene expression without abrogating the anabolic effect of parathyroid hormone. Calcif Tissue Int. 2006;78:162–170
  46. Stevenson DA, Moyer-Mileur LJ, Carey JC, Quick JL, Hoff CJ, Viskochil DH. Case-control study of the muscular compartments and osseous strength in neurofibromatosis type 1 using peripheral quantitative computed tomography. J Musculoskelet Neuronal Interact. 2005;5:145–149
  47. Abdel-Wanis ME, Kawahara N. Aetiology of spinal deformities in neurofibromatosis 1: new hypotheses. Med Hypotheses. 2001;56:400–404
  48. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin–Lowry Syndrome. Cell. 2004;117:387–398
  49. Friedman JM. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol. 2002;17:548–554
  50. Morrissy RT, Riseborough EJ, Hall JE. Congenital pseudarthrosis of the tibia. J Bone Joint Surg Br. 1981;63-B:367–375
  51. Stevenson DA, Birch PH, Friedman JM, Viskochil DH, Balestrazzi P, Boni S, et al. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet. 1999;84:413–419
  52. Crawford AH, Parikh S, Schorry EK, Von Stein D. The immature spine in type-1 neurofibromatosis. J Bone Joint Surg Am. 2007;89(Suppl 1):123–142
  53. Johnston CE 2nd. Congenital pseudarthrosis of the tibia: results of technical variations in the Charnley–Williams procedure. J Bone Joint Surg Am. 2002;84-A:1799–1810
  54. Delgado-Martínez AD, Rodríguez-Merchán EC, Olsen B. Congenital pseudarthrosis of the tibia. Int Orthop. 1996;20:192–199
  55. Fabeck L, Ghafil D, Gerroudj M, Baillon R, Delince P. Bone morphogenetic protein 7 in the treatment of congenital pseudarthrosis of the tibia. J Bone Joint Surg Br. 2006;88-B:116–118
  56. Anticevic D, Jelic M, Vukicevic S. Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report. J Pediatr Orthop B. 2006;15:220–221
  57. Lee FY, Sinicropi SM, Lee FS, Vitale MG, Roye DP, Choi IH. Treatment of congenital pseudarthrosis of the tibia with recombinant human bone morphogenetic protein-7 (rhBMP-7). A report of five cases. J Bone Joint Surg Am. 2006;88:627–633
  58. Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res. 2005;20:2044–2052
  59. Chen WJ, Jingushi S, Hirata G, Matsumoto Y, Iwamoto Y. Intramuscular bone induction by the simultaneous administration of recombinant human bone morphogenetic protein 2 and bisphosphonate for autobone graft. Tissue Eng. 2004;10:1652–1661
  60. Jeppsson C, Astrand J, Tagil M, Aspenberg P. A combination of bisphosphonate and BMP additives in impacted bone allografts. Acta Orthop Scand. 2003;74:483–489
  61. Atit RP, Crowe MJ, Greenhalgh DG, Wenstrup RJ, Ratner N. The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol. 1999;112:835–842
  62. Reed AA, Joyner CJ, Brownlow HC, Simpson AH. Human atrophic fracture non-unions are not avascular. J Orthop Res. 2002;20:593–599
  63. Hermanns-Sachweh B, Senderek J, Alfer J, Klosterhalfen B, Buttner R, Fuzesi L, et al. Vascular changes in the periosteum of congenital pseudarthrosis of the tibia. Pathol Res Pract. 2005;201:305–312
  64. Kuorilehto T, Kinnunen P, Nissinen M, Alanne M, Leskela HV, Lehenkari P, et al. Vasculopathy in two cases of NF1-related congenital pseudarthrosis. Pathol Res Pract. 2006;202:687–690
  65. Wu M, Wallace MR, Muir D. Nf1 haploinsufficiency augments angiogenesis. Oncogene. 2006;25:2297–2303

PII: S8756-3282(07)00858-7

doi: 10.1016/j.bone.2007.11.006

Bone
Volume 42, Issue 4 , Pages 616-622 , April 2008

Article Tools

* Image Usage & Resolution